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Human immunodeficiency virus-infected patients have an increased risk for depression. Despite the high
potential for drug-drug interactions, limited data on the combined use of antidepressants and antiretrovirals
are available. Theoretically, ritonavir-boosted protease inhibitors may inhibit CYP2D6-mediated metabolism
of paroxetine. We wanted to determine the effect of fosamprenavir-ritonavir on paroxetine pharmacokinetics
and vice versa and to evaluate the safety of the combination. Group A started with 20 mg paroxetine every day
for 10 days; after a wash-out period of 16 days, subjects received paroxetine (20 mg every day) plus fosam-
prenavir-ritonavir (700/100 mg twice a day) from days 28 to 37. Group B received the regimens in reverse order.
On days 10 and 37, pharmacokinetic curves were recorded. Twenty-six healthy subjects (18 females, 8 males)
were included. Median (range) age and weight were 44.4 (18.2 to 64.3) years and 68.8 (51.0 to 89.4) kg. Three
subjects were excluded (two because of adverse events; one for nonadherence). Addition of fosamprenavir-
ritonavir to paroxetine resulted in a significant decrease in paroxetine exposure: the geometric mean ratios
(90% confidence intervals) of paroxetine plus fosamprenavir-ritonavir to paroxetine alone were 0.45 (0.41 to
0.49) for the area under the concentration-time curve from 0 to 24 h (AUC0–24), 0.49 (0.45 to 0.53) for the
maximum concentration of the drug in plasma (Cmax), and 0.75 (0.71 to 0.80) for the apparent elimination
half-life (t1/2). The free fraction of paroxetine showed a median (interquartile range) increase of 30% (18 to
42%) after the addition of fosamprenavir-ritonavir. The AUC0-12, Cmax, Cmin, and t1/2 of amprenavir and
ritonavir were similar to those of historical controls. No serious adverse events occurred. Fosamprenavir-
ritonavir reduced total paroxetine exposure by 55%. This is partly explained by protein displacement of
paroxetine. We think that this interaction is clinically relevant and that titration to a higher dose of paroxetine
may be necessary to accomplish the needed antidepressant effect.
Human immunodeficiency virus (HIV)-infected patients
may have an increased risk for the development of depression,
due to social stigmatization, loss of friends or relatives to
AIDS, and other factors. The lifetime prevalence of depression
in HIV-infected patients has been estimated at 22 to 45%
(reviewed in reference 22), which is higher than for the gen-
eral, HIV-negative population (13 to 20%). Therefore, HIV-
infected patients frequently use antidepressants. A recently
published study showed that antiretroviral adherence in de-
pressed HIV-infected patients was higher in patients on anti-
depressant therapy than in depressed HIV-infected patients
that were not on antidepressant treatment (28). Thus, treat-
ment of depression is important to improve adherence of an-
tiretroviral agents.
Selective serotonin reuptake inhibitors (SSRIs) are often
considered the first choice when antidepressant drugs are
needed. They are better tolerated than tricyclic antidepres-
sants. Paroxetine is frequently prescribed in HIV-infected pa-
tients with depression (3).
One of the protease inhibitors (PIs) used in the treatment of
HIV/AIDS is fosamprenavir (Telzir/Lexiva), a prodrug of am-
prenavir. Fosamprenavir is given in combination with ritonavir
to increase the plasma exposure of amprenavir. Fosamprenavir
is a substrate for CYP3A4 and a mixed inhibitor/inducer of
CYP3A4 (summary of product characteristics for Telzir
[EMEA]). Ritonavir is a potent inhibitor of CYP450 and inhib-
its CYP3A4, CYP2D6, CYP2C9, CYP2C19, and others when
given at a high dosage, about 600 mg twice a day (BID). Given
at a low dose, 100 mg BID, ritonavir inhibits CYP3A4. Ritona-
vir is a substrate for CYP3A4 and a minor substrate for
CYP2D6 (summary of product characteristics for Norvir
[EMEA]). Paroxetine is metabolized by CYP2D6 (summary of
product characteristics for Seroxat [CBG-MEB]). At the same
time, paroxetine is a potent inhibitor of CYP2D6. Therefore,
the combination of paroxetine and fosamprenavir-ritonavir can
result in a potential drug interaction. The summary of product
characteristics for Norvir (ritonavir; EMEA) states that con-
comitant use of CYP2D6 substrates (such as paroxetine) and
ritonavir is not allowed unless the risk and benefit of this
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combination are evaluated. However, the effect of low-dose
ritonavir (100 mg BID, given as a boosting agent) on parox-
etine has not been established.
Based on the above information, the primary objective of
this trial was to determine the effect of fosamprenavir-ritonavir
on paroxetine pharmacokinetics. Furthermore, we wanted to
determine the effect of paroxetine on the pharmacokinetics of
fosamprenavir-ritonavir, the safety of the combination of fos-
amprenavir-ritonavir and paroxetine, and the effect of fosam-
prenavir-ritonavir on paroxetine pharmacodynamics.
MATERIALS AND METHODS
Study design and dosing of study drugs. This was an open-label, multiple-
dose, two-arm, two-sequence, two-period, pharmacokinetic drug-drug interac-
tion study in 26 healthy subjects. In group A, 13 subjects received 10 oral doses
of 20 mg of paroxetine once daily (QD) (1 capsule of 20 mg of Seroxat taken at
approximately 8:00 a.m. with a meal) during the first period of 10 days. After a
wash-out period of 16 days (study days 11 to 27), all subjects in group A received
10 oral doses of 20 mg of paroxetine once daily, 20 oral doses of 700 mg of
fosamprenavir twice daily (1 tablet of 700 mg of Telzir/Lexiva taken at approx-
imately 8:00 a.m. and 8:00 p.m. with a meal), and 20 oral doses of ritonavir twice
daily (1 capsule of Norvir 100 mg taken at approximately 8:00 a.m. and 8:00 p.m.
with a meal) during the second phase of 10 days (study days 28 to 37). In group
B, 13 other subjects received the regimens in reverse order.
A crossover design with a wash-out period of 16 days was chosen to exclude
period and carryover effects on the pharmacokinetics of amprenavir-ritonavir
and paroxetine.
Study population. This trial was conducted with healthy males and females
between 18 and 65 years of age at the day of first dosing. Subjects did not smoke
more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior
to the first dosing, had a Quetelet Index (body mass index) of 18 to 30 kg/m2, and
were able and willing to sign the informed consent form prior to screening
evaluations. Subjects had to be in good age-appropriate health, as established by
medical history, physical examination, electrocardiography, biochemistry, hema-
tology, and urinalysis testing within 3 weeks prior to the first dose. The main
exclusion criteria were a history of psychiatric illness, poor and ultrarapid
CYP2D6 metabolizer status as determined by genotyping, history of sensitivity/
idiosyncrasy to fosamprenavir, ritonavir, paroxetine, or chemically related com-
pounds or excipients, a positive HIV test, a positive hepatitis B or C test, or
therapy with any drug for 2 weeks preceding dosing (except for acetaminophen,
hormonal contraceptives, and loperamide). Other exclusion criteria were history
of or current abuse of drugs, alcohol, or solvents and participation in a drug trial
or donation of blood within 60 days prior to the first dose. Pregnant or breast-
feeding females and female subjects of childbearing potential who were not
willing to take precautions in order to prevent a pregnancy were also excluded.
CYP2D6 genotyping. DNA samples were analyzed at the Laboratory of An-
thropogenetics, Radboud University Nijmegen Medical Centre. The genotyping
of CYP2D6*3, CYP2D6*4, and CYP2D6*6 was performed with pyrosequencing
technology (12). CYP2D6*5 and CYP2D6*xn alleles were detected with XL-
PCRs (17, 24). Depending on the presence of the different alleles, poor (ho-
mozygote for alleles CYP2D6*3, *4, *5, and *6) and ultrarapid (at least one
CYP2D6*xn allele and none of the other alleles) metabolizers were excluded.
Safety assessments and pharmacokinetic sampling. Blood samples for phar-
macokinetics were collected throughout a 12-h period (0, 1, 2, 3, 4, 5, 6, 8, 10, and
12 h) after dosing on days 10 and 37 for amprenavir-ritonavir and throughout a
24-h period (0, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h) after dosing for paroxetine.
Trough levels, just before intake of the drugs, were determined on days 1, 4, 8,
28, 31, and 35.
Serum biochemistry, hematology, and urinalysis were checked on days 1, 4, 8,
10, 28, 31, 35, and 37. Adverse events and physical condition of the subjects were
assessed during the same visits. A pregnancy test for women and screening for
drugs of abuse were conducted on days 1, 10, 28, and 37.
Pharmacodynamics. Serotonin is transported into blood platelets and central
neurons by a similar active uptake transporter mechanism. It has been reported
that changes in serotonin transport activities in platelets, induced by serotonin
reuptake inhibitors, may be a potential surrogate marker of their effectiveness
(serotonin reuptake inhibition) at the synaptosomal membrane in the brain
(reviewed in reference 8). Therefore, serotonin concentrations in platelets were
measured at the Laboratory of Pediatrics and Neurology at the Radboud Uni-
versity Nijmegen Medical Centre to determine the peripheral pharmacodynamic
effect of paroxetine. For the determination of serotonin concentrations, venous
whole blood was collected predose on days 1, 10, 28, and 37 of the trial. While
the blood was clotting, platelets released serotonin, which was measured in
serum.
Compliance. Study personnel supervised all medication intakes during the
visits to the clinical trial unit on days 1, 4, 8, 10, 28, 31, 35, and 37. The exact times
of dosing were recorded. Drug intakes by the subjects at home were monitored
by the use of MEMS caps (Aardex Ltd., Zug, Switzerland), which record the
opening of the medication bottle. Furthermore, subjects were asked to write
down the exact times of medication intake in a booklet.
Bioanalysis of amprenavir-ritonavir and paroxetine (total and unbound) con-
centrations in plasma. Plasma samples were analyzed for amprenavir, ritonavir,
and paroxetine (total concentrations) at the Department of Clinical Pharmacy,
Radboud University Nijmegen Medical Centre. The Department of Clinical
Pharmacy has established a high-pressure liquid chromatography (HPLC) assay
for amprenavir and ritonavir, derived from a reversed-phase HPLC method
which was published previously (10). The method involves liquid-liquid extrac-
tion from plasma, followed by HPLC with an OmniSpher 3 C18 column (100 by
4.6 mm) and UV detection at 215 nm. For the determination of amprenavir and
ritonavir in our trial, we used acetonitrile and 50 mM phosphate buffer (pH 5.60)
as the mobile phase. The acetonitrile concentration was increased from 35% to
54% during a 21-min period; thereafter, it was returned to 35%. The accuracy for
amprenavir was 102% at 0.15 mg/liter, 105% at 1.5 mg/liter, and 103% at 7.5
mg/liter. For ritonavir, the accuracy was 101%, 104% and 103%, respectively.
The precision (within-day; coefficient of variation; n  15) for amprenavir was
3.98%, 4.05%, and 2.55% at 0.15, 1.5 and 7.5 mg/liter, respectively. For ritonavir,
the precision (within-day; coefficient of variation; n 15) was 3.22%, 1.70%, and
0.89%, respectively. The precision (between-day; coefficient of variation; n  3)
for amprenavir was 5.04%, 2.67%, and 1.18% at 0.15, 1.5 and 7.5 mg/liter,
respectively; for ritonavir it was 3.64%, 1.17%, and 1.10%, respectively. The
calibration curves were linear over concentration ranges of 0.10 to 30 mg/liter for
amprenavir and 0.045 to 30 mg/liter for ritonavir.
Total (bound plus unbound) plasma levels of paroxetine were analyzed by
using a validated reversed-phase HPLC method. This method consists of a
liquid-liquid extraction step followed by HPLC. Briefly, 0.5 ml plasma was vor-
texed and centrifuged with 50 l internal standard (dibucaine in methanol-
water), 0.5 ml 0.2 M NH4OH, and 5 ml tert-butylmethylether. The organic layer
was removed and dried. Then, 0.25 mM potassium hydrogen phosphate in ace-
tonitrile (60/40) was added and vortexed. These samples were run with calibra-
tion curves and quality controls on a 3.5-m SymmetryShield RP18 (150 by 4.6
mm; Waters) column with an in-line filter (Sure-guard) and acetonitrile–25 mM
potassium hydrogen phosphate as the mobile phase. The acetonitrile concentra-
tion was 34% for 6 min, then increased to 60% for 2.5 min and returned to 34%
for the final 4.5 min. The total run time was 13 min. Paroxetine and the internal
standard were detected with fluorescence (extinction at 296 nm; emission at 350
nm). The accuracy for paroxetine was 95.9 to 104.1% over a concentration range
of 0.0025 to 0.25 mg/liter. The overall precision (coefficient of variation) was
4.2% or less over a concentration range of 0.0025 to 0.25 mg/liter. The calibration
curve was linear over a concentration range of 0.0025 to 0.25 mg/liter.
Unbound-paroxetine plasma concentrations were measured at Analytical Bio-
chemical Laboratories, Assen, The Netherlands, to determine the effect of fos-
amprenavir-ritonavir on the free fraction of paroxetine. The percentage of un-
bound paroxetine in human plasma samples was determined via equilibrium
dialysis using a Dianorm equilibrium dialyzer system. With this equilibrium
dialyzer, free paroxetine was separated from the bound fraction using dialysis
membranes with a molecular weight cutoff of 5,000. Human plasma samples were
dialyzed against a buffer solution (pH 7.4) containing potassium biphosphate (1.9
g/liter), disodium phosphate (8.1 g/liter), sodium chloride (4.1 g/liter), and dex-
tran (molecular weight, 64,000 to 76,000; 30 g/liter) for 4 h. After dialysis, the
buffer compartment was diluted with blank human heparin plasma (1:1), and the
plasma fraction was diluted with dialysis buffer solution (1:1). Both the free (i.e.,
unbound) and the total maximum concentration of paroxetine were analyzed by
a validated LC-tandem mass spectrometry method. The samples were run on a
4-m Synergi RP80A Fusion (75 by 4.6 mm; Phenomenex) column and ammo-
nium formate–formic acid buffer–methanol as the mobile phase, which was
applied as a gradient. Finally, the percent free paroxetine was calculated. We
chose to determine maximum concentrations of the unbound paroxetine, be-
cause it was not possible to measure trough levels, which would be lower than the
lower limit of quantification of paroxetine. The accuracy of the quality control
samples for the free concentration of paroxetine was 107.5% at 0.150 ng/ml,
106.6% at 1.50 ng/ml, and 104.3% at 40.0 ng/ml. The overall precision (coefficient
of variation) was 3.2%, 5.3%, and 4.3% at 0.150, 1.50 and 40.0 ng/ml, respec-
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tively. The calibration curve was linear over the concentration range of 0.0500 to
50.0 ng/ml paroxetine in human plasma.
Pharmacokinetic analysis. Pharmacokinetic parameters for paroxetine, am-
prenavir, and ritonavir were calculated by noncompartmental methods by use of
WinNonlin software (version 4.1; Pharsight Corporation, Mountain View, CA)
and the log/linear trapezoidal rule. Based on the individual plasma concentra-
tion-time data, the following pharmacokinetic parameters were determined: the
area under the plasma concentration-time curve from 0 to 24 h after intake for
paroxetine (AUC0–24) and from 0 to 12 h after intake for amprenavir and
ritonavir (AUC0–12; in milligram  hours per liter), the maximum concentration
of the drugs in plasma (Cmax; in milligrams per liter), the trough concentration
in plasma (Cmin; 12 h after intake for amprenavir-ritonavir; 24 h after intake for
paroxetine; in milligrams per liter), the apparent elimination half-life (t1/2; in
hours) and the apparent oral clearance (CL/F; in liters per hour).
Sample size and statistical analysis. The power analysis for proving equiva-
lence in a crossover design according to the method of Hauschke et al. (16) was
used for calculating the sample size for this trial. The sample size was determined
to attain a power of 80% at an  level of 0.05 in the case of an equivalence range
(0.8 to 1.25), an intraindividual coefficient of variation of 20%, and an intersub-
ject coefficient of variation of 65% (4, 16). The calculated sample size was 20 (10
per group) subjects. We estimated a drop-out rate of 25% based on previous
pharmacokinetic interaction studies in healthy volunteers carried out by our
department. Therefore, a total of 26 subjects were included in this trial to ensure
completed data from 20 subjects.
For the determination of a clinically relevant interaction, we used the bio-
equivalence approach (26). Geometric means were calculated for the AUC0-12
(amprenavir-ritonavir), AUC0-24 (paroxetine), Cmin, Cmax, t1/2, and CL/F. Geo-
metric mean ratios (GMR) with 90% confidence intervals (CI) were calculated
after log transformation of within-subject ratios for AUC0-24, Cmax, and t1/2 for
paroxetine. A GMR with 90% CI falling entirely within 0.80 to 1.25 was consid-
ered as bioequivalence.
Statistical evaluations were carried out using SPSS for Windows, version 12.0.1
[SPSS Inc, Chicago, IL].
RESULTS
Baseline characteristics. Twenty-six healthy subjects, 8
males and 18 females, with a median age of 44.4 years (range,
18.2 to 64.3), were included in this trial. Median (range)
weight, height and body mass index were 68.8 kg (51.0 to 89.4),
1.71 m (1.58 to 1.83) and 24.0 kg/m2 (17.5 to 29.7), respectively.
Twenty-four subjects were Caucasians, one was Oriental, and
one had a Mediterranean background.
Study completion. Compliance by 25 of the 26 subjects was
good, as indicated by the subject’s statements about the intake
of the previous doses, the numbers of tablets and capsules in
the returned vials, the booklets, and the MEMS caps (data not
shown). One subject missed one dose of paroxetine on day 3
because of nausea; five subjects took paroxetine BID instead of
QD for 1 or 2 days in the beginning of the trial period when
paroxetine was combined with fosamprenavir-ritonavir, which
had to be taken twice daily; all other subjects took all doses of
paroxetine and fosamprenavir-ritonavir at the right time
points.
One female subject was excluded for pharmacokinetic data
analysis because of significant nonadherence (deviating plasma
paroxetine levels and MEMS data indicating that medication
bottles were not opened properly), discovered after the end of
the study. Two subjects (one male and one female) discontin-
ued the use of trial medication because of adverse events (as
described below).
Pharmacokinetics. Pharmacokinetic parameters were calcu-
lated for 23 evaluable subjects. The geometric mean (95% CI)
AUC0–24, Cmax, Cmin, t1/2, and CL/F of paroxetine (total un-
bound and protein-bound paroxetine, given alone without
fosamprenavir-ritonavir) were 0.59 mg  h/liter (0.51 to 0.85),
0.034 mg/liter (0.030 to 0.047), 0.019 mg/liter (0.017 to 0.030),
21 h (18 to 27), and 33.1 liters/h (29.1 to 46.9), respectively,
which are similar to data from other studies with the same
dosage (4, 14, 23). Table 1 shows the GMR of the AUC0-24,
Cmax, and t1/2 comparing paroxetine given alone and in com-
bination with fosamprenavir-ritonavir. The AUC0-24, Cmax,
and t1/2 of paroxetine alone compared to paroxetine with
fosamprenavir-ritonavir were considered not bioequivalent.
The GMR for the AUC0-24 of paroxetine was 0.45 (90% CI,
0.41 to 0.49), indicating that the AUC0-24 of paroxetine (total
of bound and unbound concentration) was significantly de-
creased by fosamprenavir-ritonavir. Figure 1 shows the phar-
macokinetic 24-h curves of paroxetine, alone and in combina-
tion with fosamprenavir-ritonavir.
The free fraction (unbound paroxetine divided by total of
unbound and bound paroxetine concentration) was increased
in all subjects after the addition of fosamprenavir-ritonavir to
paroxetine. The median (interquartile range) increase was
30% (18 to 42%), indicating that relatively more unbound
paroxetine was present in combination with fosamprenavir-
ritonavir and that protein displacement had occurred.
The free/unbound Cmax of paroxetine in combination with
fosamprenavir-ritonavir was lower than that of paroxetine
given alone by 39.8% (median; interquartile range, 26.9 to
45.5%).
The pharmacokinetic parameters of amprenavir and ritona-
vir are shown in Table 2. The pharmacokinetic parameters of
amprenavir and ritonavir were similar to the results of other
trials (2, 7, 27; summaries of product characteristics for Norvir
and Telzir [EMEA]), suggesting that paroxetine did not affect
the pharmacokinetics of amprenavir-ritonavir. We did not
compare the pharmacokinetics of fosamprenavir-ritonavir to a
control group, which is a limitation of our trial. Figure 2 shows
the median curve of amprenavir compared to historical con-
trols (27).
Paroxetine levels in the two groups were compared to ex-
clude a period effect or a carryover effect on the pharmacoki-
TABLE 1. Comparison of pharmacokinetic parameters of the combination of paroxetine and fosamprenavir/ritonavir and
paroxetine alone (n  23)
Period and regimen
Geometric mean (95% CI) [GMR, period 2/period 1 (90% CI)]
AUC0–24 (mg  h/liter) Cmax (mg/liter) t1/2 (h)
1. Paroxetine (20 mg QD) 0.59 (0.51–0.85) 0.034 (0.030–0.047) 21.1 (18.4–27.1)
2. Paroxetine (20 mg QD) 
fAPV/r (700/100 mg BID)a
0.27 (0.24–0.36) [0.45 (0.41–0.49)] 0.017 (0.015–0.022) [0.49 (0.45–0.53)] 15.9 (13.4–20.9) [0.75 (0.71–0.80)]
a fAPV/r, fosamprenavir-ritonavir.
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netic parameters. Paroxetine concentration ratios between
groups A and B showed no difference (independent-samples t
test, P  0.238).
Pharmacodynamics. Paired serotonin concentrations in
platelets could be determined for only 17 subjects, because at
least one of the whole-blood samples of the other subjects was
hemolytic. The median decrease in serotonin concentration in
platelets after a 10-day use of paroxetine alone was 87% com-
pared to baseline. The median decrease of serotonin concen-
trations after a 10-day use of paroxetine in combination with
fosamprenavir-ritonavir was 81% compared to baseline sero-
tonin concentrations. There was no significant difference in
change in serotonin concentration with paroxetine alone ver-
sus paroxetine in combination with fosamprenavir-ritonavir
(Wilcoxon signed-ranks test, P  0.554).
Adverse events and safety assessments. Table 3 shows the
most frequently occurring adverse events (defined as any ad-
verse event experienced by two or more persons) during the
different periods of the trial (paroxetine alone and paroxetine
in combination with fosamprenavir-ritonavir). No serious ad-
verse events were reported. Two subjects withdrew because of
adverse events: one female subject experienced grade III diar-
rhea, and another male subject had grade II nausea; both
subjects were using paroxetine and fosamprenavir-ritonavir
when they withdrew. Eight subjects (two males and six fe-
males) experienced rashes at the end of the period in which
they received paroxetine combined with fosamprenavir-ritona-
vir; one of these subjects had a grade III rash. Four of the
subjects experiencing rashes received cetirizine. The subject
with the severe rash also received clemastine and hydrocorti-
sone (once, subcutaneously). The other adverse events were
mild. None of the subjects experienced permanent adverse
effects due to the use of trial medication.
As shown in Table 3, seven subjects experienced diarrhea
when paroxetine was combined with fosamprenavir-ritonavir.
These subjects had a significantly smaller difference in parox-
etine AUC and Cmax (total concentrations) between the period
with paroxetine alone and the period in which the combination
of paroxetine and fosamprenavir-ritonavir was used than sub-
jects who did not experience diarrhea (P  0.040 and P 
0.048, respectively; independent-samples t test). So, fosam-
prenavir-ritonavir-associated diarrhea did not cause a reduced
FIG. 1. Pharmacokinetic curves (geometric mean and standard deviation) of paroxetine alone and in combination with fosamprenavir-ritonavir
(fAPV/r) (n  23).
TABLE 2. Pharmacokinetic parameters of amprenavir and ritonavir (n  23) compared to population data
Drug and data source
Geometric mean (95% CI)
AUC0–12 (mg  h/liter) Cmin (mg/liter) Cmax (mg/liter) t1/2 (h)
Amprenavir
This study 44.1 (40.5–50.2) 2.7 (2.4–3.2) 5.8 (5.4–6.6) 11.5 (10.1–15.2)
Population dataa 39.6 (34.5–45.3) 2.1 (1.8–2.5) 6.1 (5.4–6.9) 15–23
Ritonavir
This study 5.1 (4.5–6.2) 0.18 (0.16–0.23) 0.92 (0.81–1.3) 4.1 (3.6–5.0)
Population datab 5.8 (4.8–7.0) 0.15 (0.11–0.22) 1.2 (0.98–1.5) 3–5
a Data from references 7 and 27 and the summary of product characteristics for Telzir (EMEA).
b Data from reference 27 and the summary of product characteristics for Norvir (EMEA).
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absorption of paroxetine, because if it had, we would have
expected to find a greater difference in AUC and Cmax between
the two trial periods in patients experiencing diarrhea.
DISCUSSION
The decrease of 55% in paroxetine plasma exposure when
paroxetine was combined with fosamprenavir-ritonavir was un-
expected. Based on the fact that ritonavir and paroxetine are
both inhibitors of CYP2D6 (summaries of product character-
istics for Seroxat [CBG-MEB] and Norvir [EMEA]), we ex-
pected that either ritonavir would inhibit the metabolism of
paroxetine, which would have caused higher paroxetine levels,
or paroxetine would inhibit ritonavir metabolism and that the
associated increase in ritonavir levels would have had a greater
booster effect and increased amprenavir levels.
We could think of four possible explanations for the de-
crease in paroxetine plasma levels: (i) displacement of protein
binding of paroxetine by fosamprenavir and/or ritonavir; (ii)
CYP3A acts as a secondary metabolic pathway for paroxetine,
induced by fosamprenavir; (iii) induction of CYP2D6-medi-
ated metabolism of paroxetine by fosamprenavir and/or ritona-
vir; (iv) decreased absorption of paroxetine by fosamprenavir
and/or ritonavir.
The first and most likely explanation (displacement of
protein binding) is possible because paroxetine (95% [sum-
mary of characteristics; CBG-MEB]), amprenavir (90%
[summary of characteristics; EMEA]) and ritonavir (98 to
99% [summary of characteristics; EMEA]) are all highly
bound to the same plasma proteins (alpha-1 acid glycoprotein
and albumin). The Food and Drug Administration’s prescrib-
ing information for Prezista (darunavir), a novel PI, describes
the same effect on total paroxetine concentrations when par-
oxetine is combined with darunavir-ritonavir. In our trial we
found a median increase of 30% in the paroxetine-free frac-
tion, which is indicative of protein displacement. An interac-
tion caused by protein displacement is usually not clinically
relevant, because after establishment of a new equilibrium, the
free (i.e., effective) concentration of a drug is not changed.
However, in this trial the free Cmax of paroxetine decreased by
40%, so the interaction can be only partly explained by protein
displacement. In our trial we did not find a significant differ-
ence in change in serotonin concentration in platelets using
paroxetine alone versus paroxetine in combination with fosam-
prenavir-ritonavir (Wilcoxon signed-ranks test: P  0.554). A
possible explanation for a lack of a pharmacodynamic effect
could be that the reuptake of serotonin is already saturated
with a low paroxetine concentration. Furthermore, whole-
blood serotonin levels are indicative of serotonin reuptake in
plasma and most likely also reflect the activity taking place in
the central neurons, but depletion of platelet serotonin is not
a reliable index of antidepressant efficacy. Previously, no cor-
FIG. 2. Median pharmacokinetic curve of amprenavir (n  23) compared to historical controls (27).
TABLE 3. Numbers of subjects experiencing adverse eventsa
System Adverse event
No. of subjects in period
Paroxetine
alone
(n  25)
Paroxetine with
fosamprenavir-
ritonavir
(n  26)
Gastrointestinal Diarrhea 2 7
Nausea 4 13
Musculoskeletal and
connective tissue
Stiff jaws 3
Nervous Headache 3 4
Flat emotions 4
Tiredness 8 8
Dizziness 4
Skin and subcutaneous Rash 8
Overall 37 62
a Adverse events reported by two or more subjects per group.
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relation was found between changes in platelet levels and the
Hamilton depression rating scale scores (8).
The second explanation (induction of metabolism) is based
on data that (fos)amprenavir can induce CYP3A4 (summary of
characteristics, EMEA). A trial combining phenytoin (a
CYP3A4 inducer) with paroxetine showed decreased parox-
etine levels (data on file; GlaxoSmithKline). These data are,
however, in contrast with those of other trials that showed no
interactions between paroxetine and two well-known CYP3A4
substrates: alprazolam (6) and terfenadine (20). Another fac-
tor which makes this explanation less likely is that ritonavir is
a very strong inhibitor of CYP3A4 (summary of characteristics,
EMEA) and would increase paroxetine levels if paroxetine was
metabolized through CYP3A4.
The third explanation (induction of CYP2D6-mediated par-
oxetine metabolism) is not likely, as no data about induction of
CYP2D6 by fosamprenavir-ritonavir have been reported so
far. Furthermore, it is known that CYP2D6 is not easily in-
duced. Rifampin, which is a strong inducer, decreases plasma
levels of CYP2D6 substrates by only approximately 25% (5,
11). Our trial showed a decrease in paroxetine AUC0-24 of
55%. Moreover, in a previous study, our group found a modest
inhibitory effect of 100 mg ritonavir BID on the activity of
CYP2D6 (1).
Decreased absorption of paroxetine is our fourth and final
explanation. So far, no effect of fosamprenavir-ritonavir on
absorption of other drugs has been described. We thought that
a decrease in absorption could have been indicated by the fact
that diarrhea occurred more frequently when fosamprenavir-
ritonavir was combined with paroxetine than when paroxetine
was given alone. However, the subjects with diarrhea had a
significantly lower difference in AUC and Cmax between the
two trial periods (with or without fosamprenavir-ritonavir)
than patients without diarrhea.
We found that the half-life of paroxetine was decreased by
25% in combination with fosamprenavir-ritonavir. It has been
reported that a decrease in protein binding results in a shorter
half-life. However, this has been described mostly for drugs
with a relatively small apparent volume of distribution (0.25
liter/kg) (13) and the apparent volume of distribution of par-
oxetine is larger (about 8.7 liters/kg) (19); paroxetine is exten-
sively distributed into tissues (19; summary of characteristics;
CBG-MEB). Furthermore, the t1/2 of paroxetine is approxi-
mately 1 day according to the literature. The t1/2 was calculated
during steady state with a dosing interval of 24 h and the last
two blood samples taken at 12 and 24 h after intake, so there
is a large uncertainty under these conditions. Therefore, one
should be very cautious with the interpretation of changes
in t1/2.
No serious adverse events were reported during the trial.
Surprisingly, rashes occurred in eight subjects when paroxetine
was combined with fosamprenavir-ritonavir. We expect the
rash to be an adverse event of fosamprenavir, as it is described
as “common” (i.e., occurring in 1/100 and 1/10 subjects) in
the summary of product characteristics of fosamprenavir
(EMEA), but we cannot explain the higher incidence in our
trial than mentioned in the summary of product characteristics.
The combination of fosamprenavir-ritonavir with paroxetine
seems safe, but larger studies are needed to confirm our ob-
servation, as the sample size of our trial was too small to draw
definite conclusions about safety.
Only a few interactions between antiretroviral drugs and
antidepressants have been investigated so far (25). As men-
tioned above, Aarnoutse et al. found a modest inhibitory effect
of ritonavir (100 mg BID) on the activity of CYP2D6 in healthy
extensive metabolizers (1), which resulted in a 26% increase in
the geometric mean AUC of desipramine (a tricyclic antide-
pressant). Furthermore, coadministration of 30 mg fluoxetine
(SSRI; inhibitor of CYP2D6) BID and ritonavir as a single
dose in 16 healthy subjects resulted in a 19% increase in ritona-
vir AUC. Fluoxetine concentrations were not measured. How-
ever, postmarketing experience has revealed reports of cardiac
and neurologic events when ritonavir and fluoxetine have been
combined (21; summary of characteristics [EMEA]), and sev-
eral cases of the serotonin syndrome in HIV-infected patients
receiving antiretroviral therapy and fluoxetine have been re-
ported (9). Moreover, no pharmacokinetic interaction between
escitalopram (SSRI; substrate for CYP3A4, CYP2C19, and
CYP2D6) and ritonavir was observed. The fourth study we
found was an in vitro study with bupropion (an antidepressant
and smoking cessation aid) and ritonavir which showed that
ritonavir has a low 50% inhibitory concentration for inhibition
of bupropion hydroxylation through CYP2B6, indicating the
possibility of a clinically important CYP2B6 inhibition in vivo
(18). No study combining bupropion with ritonavir in vivo has
been performed yet. Finally, short-term low-dose administra-
tion of ritonavir (four doses of 200 mg) showed a decreased
oral clearance of trazodone (CYP3A substrate) and increases
in AUC and adverse reactions (15). We think that our trial
contributes to the limited data on interactions between anti-
depressants and antiretroviral agents.
In conclusion, our data show an interaction between parox-
etine and fosamprenavir-ritonavir. Fosamprenavir-ritonavir
decreases the AUC0-24 of paroxetine (total concentration) by
55%. The Cmax of the unbound concentrations was decreased
by 40%. We think that this interaction is clinically relevant and
that titration to a higher dose of paroxetine may be necessary
to accomplish the needed antidepressant effect. More research
is necessary to fully elucidate the mechanism behind this in-
teraction. It appears that paroxetine does not have an effect on
the pharmacokinetics of amprenavir-ritonavir.
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